What is Armata Pharmaceuticals Inc (ARMP) stock price today?

Armata Pharmaceuticals Inc (ARMP) currently trades at $9.87 per share. The stock has a market capitalization of $473.30M and a P/E ratio of —x.

Is ARMP stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Armata Pharmaceuticals Inc has a Smart Value Score of 19/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Armata Pharmaceuticals Inc's revenue and earnings?

Armata Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $4.90M with profit margins of 0.00%. Earnings per share (EPS) is $-4.80.

Is ARMP stock overvalued or undervalued?

Based on our DCF model, Armata Pharmaceuticals Inc's intrinsic value is $38.31, representing a margin of safety of 79.12%. The stock currently trades at a P/E of —x.

ARMP

Armata Pharmaceuticals Inc

NYSE MKT: ARMP · HEALTHCARE · BIOTECHNOLOGY

$9.87

+3.35% today

Updated 2026-04-30

Market cap

$473.30M

P/E ratio

—

P/S ratio

96.51x

EPS (TTM)

$-4.80

Dividend yield

—

52W range

$1 – $15

Volume

0.1M

Market cap

$473.30M

P/E ratio

—

P/S ratio

96.51x

EPS (TTM)

$-4.80

Dividend yield

—

52W range

$1 – $15

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$17.50

+77.30%

12-Month target

—

Intrinsic (DCF)

$38.31

Margin of safety

+79.12%

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 79.12% below intrinsic value

Risks

- Thin margins at 0.00%

- Negative free cash flow $-6.73M

- Revenue declining -12.10% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$5.51M	$4.53M	$5.17M	$4.90M	$4.90M
Net income	$-36.92M	$-69.05M	$-18.92M	$-173.80M	$-124.30M
EPS	—	—	—	—	$-4.80
Free cash flow	$-34.69M	$-55.57M	$-39.43M	$-26.30M	$-6.73M
Profit margin	-670.24%	-1,524.51%	-365.60%	-3,544.03%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-14	KYME, PIERRE	Sale	1,030	$10.54
2026-03-14	BIRX, DEBORAH	Sale	4,919	$10.54
2026-03-09	SCHLESINGER, SARAH J.	Buy	25,640	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ARMP	$473.30M	19	2.7	2.5	6.7	5.0	+79.12%	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Armata Pharmaceuticals Inc trades at $9.87. Our Smart Value Score of 19/100 indicates the stock is weak. TTM revenue stands at $4.90M. Our DCF model estimates intrinsic value at $38.31.

Frequently asked questions

What is Armata Pharmaceuticals Inc's stock price?

Armata Pharmaceuticals Inc (ARMP) trades at $9.87.

Is Armata Pharmaceuticals Inc overvalued?

Smart Value Score 19/100 (Grade F, Strong Sell). DCF value $38.31.

What is the price target of Armata Pharmaceuticals Inc (ARMP)?

The analyst target price is $17.50, representing +77.3% upside from the current price of $9.87.

What is the intrinsic value of Armata Pharmaceuticals Inc (ARMP)?

Based on our DCF model, intrinsic value is $38.31, a +79.1% margin of safety versus $9.87.

What is Armata Pharmaceuticals Inc's revenue?

TTM revenue is $4.90M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

Quick metrics

P/S ratio96.51x

ROE-3,439.00%

Beta1.40

50D MA$10.53

200D MA$6.11

Shares out0.04B

Float0.01B

Short ratio—

Avg volume0.1M

Performance

1 week-27.86%

1 month-4.69%

3 months+46.99%

YTD+55.41%

1 year—

3 years—

5 years—

Compare

ARMP vs LLY →ARMP vs JNJ →ARMP vs ABBV →Stock screener →